Nova Eye Medical Limited
ELXMF · OTC
6/30/2025 | 12/31/2024 | 6/30/2024 | 12/31/2023 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 26.4% | -2% | 30.1% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 63.2% | 66.2% | 85.4% | 13% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -9.4% | -40.1% | -11.7% | -41.3% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -22.4% | -41.7% | -24% | -55.5% |
| EPS Diluted | -0.014 | -0.024 | -0.015 | -0.029 |
| % Growth | 41.3% | -62.1% | 49.5% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |